Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial

ContextLong-acting recombinant human growth hormone (rhGH) has transformed growth hormone deficiency (GHD) treatment. However, the possibility and rationality for flexible time regimen are pending.ObjectiveWe studied the efficacy of biweekly versus weekly PEGylated rhGH (PEG-rhGH) therapy in GHD chi...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Chengjun Sun, Biao Lu, Yu Liu, Yaqin Zhang, Haiyan Wei, Xu Hu, Pei Hu, Qian Zhao, Yanling Liu, Kan Ye, Kan Wang, Zaiyan Gu, Zheng Liu, Jin Ye, Hongxiao Zhang, Hong Zhu, Zhihong Jiang, Yanjie Liu, Naijun Wan, Chengming Yan, Jianying Yin, Lirong Ying, Feng Huang, Qingjin Yin, Li Xi, Feihong Luo, Ruoqian Cheng
Format:	article
Langue:	EN
Publié:	Frontiers Media S.A. 2021
Sujets:	growth hormone deficiency PEGylated recombinant human growth hormone PEG-rhGH IGF-2 children Diseases of the endocrine glands. Clinical endocrinology RC648-665
Accès en ligne:	https://doaj.org/article/342716233f3f4e22bd958dab3aed79f3
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Reduced Effectiveness and Comparable Safety in Biweekly vs. Weekly PEGylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency: A Phase IV Non-Inferiority Threshold Targeted Trial

Documents similaires